The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...
Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...
Treatment with Akeega plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54% compared to placebo/abiraterone acetate plus ...
Soy Nómada on MSN
Discover the signs of prostate cancer, according to experts
Exploring common changes in your body that deserve a closer look for long-term health and wellness. Stay informed about these essential health markers.
Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results